Protalix BioTherapeutics Reports Q3 2026 Revenue Growth Driven by Elfabrio Sales
Protalix BioTherapeutics (PLX) reported strong third-quarter 2026 financial results, with total revenue reaching $21.9 million, up from $17.9 million in the prior year period. This growth was primarily driven by increased sales of Elfabrio to commercial partner Chiesi. The company also reported a net income of $4.0 million ($0.05 per diluted share), compared to $2.4 million in the same quarter last year. Looking ahead, Protalix reaffirmed its full-year 2026 revenue guidance between $78.0 million and $83.0 million. While the company noted a delay in the PRX-119 program, management highlighted significant market opportunities for Elfabrio in the Fabry disease space and potential blockbuster status for PRX-115 in treating uncontrolled gout. The company maintains a solid liquidity position with $48.5 million in cash and bank deposits as of September 30, 2026.
Tickers: $PFE
Topics: Clinical Pipeline Net Income R&D Expenses Revenue Growth